AU Patent

AU2020205261A1 — Methods of treating cancer

Assigned to Epizyme Inc · Expires 2020-08-06 · 6y expired

What this patent protects

The present invention relates to methods of treating cancer by administering the EZH2 inhibitor compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non therapeutic purposes.

USPTO Abstract

The present invention relates to methods of treating cancer by administering the EZH2 inhibitor compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non therapeutic purposes.

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: AU2020205261A1
Jurisdiction: AU
Classification: —
Expires: 2020-08-06
Drug substance claim: No
Drug product claim: No
Assignee: Epizyme Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.